🇺🇸 FDA
Patent

US 11530239

Methods and compositions for treating diseases and conditions associated with gonadotropin releasing hormone receptor

granted A61KA61K38/00A61P

Quick answer

US patent 11530239 (Methods and compositions for treating diseases and conditions associated with gonadotropin releasing hormone receptor) held by The Board of Regents of the University of Oklahoma expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Oklahoma
Grant date
Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K38/00, A61P, A61P15/08, A61P35/00